MEDICAL DEVICES
Untitled Page
MammaPrint predicts response to cancer therapy
Huntington Beach-based Agendia's MammaPrint aids in breast cancer treatment programs.
By Kristen SchottPublished: December 15, 2008 10:00 AM
Agendia, which specializes in molecular cancer diagnostics, is reporting that its MammaPrint program can predict the response to neoadjuvant chemotherapy – therapy given to women before breast surgery.
The results were released during the 2008 San Antonio Breast Cancer Symposium, which took place Dec. 10-14. The study analyzed the link between the pathological complete response rate (it measures the effectiveness of a therapy) and the data from MammaPrint, which helps physicians to determine accurate treatment plans and breast cancer recurrence.
"Physicians are increasingly supportive of MammaPrint in clinical practice because they believe it provides them with invaluable information for patient treatment planning," says Dr. Richard Bender, Agenida's chief medical officer. "MammaPrint's ability to accurately determine high-risk patient responsiveness to chemotherapy both confirm and speak to the confidence physicians express in this state-of-the-art genomic breast cancer test."
A series of 167 patients who received neoadjuvant chemotherapy for stage two or three breast cancer were analyzed to find MammaPrint's predictive abilities. Twenty percent of the patients in the poor prognosis group achieved a pathological complete response, and after 25 months, only 19 of them relapsed. None of the patients with a good prognosis received a response, which suggests tumors with a poor prognosis rating from MammaPrint are sensitive to chemotherapy.
Other medical headlines:
Radix Acupuncture & Chiropractic opens
Leading women's health site gets makeover
|
||||
|
The results were released during the 2008 San Antonio Breast Cancer Symposium, which took place Dec. 10-14. The study analyzed the link between the pathological complete response rate (it measures the effectiveness of a therapy) and the data from MammaPrint, which helps physicians to determine accurate treatment plans and breast cancer recurrence. "Physicians are increasingly supportive of MammaPrint in clinical practice because they believe it provides them with invaluable information for patient treatment planning," says Dr. Richard Bender, Agenida's chief medical officer. "MammaPrint's ability to accurately determine high-risk patient responsiveness to chemotherapy both confirm and speak to the confidence physicians express in this state-of-the-art genomic breast cancer test." A series of 167 patients who received neoadjuvant chemotherapy for stage two or three breast cancer were analyzed to find MammaPrint's predictive abilities. Twenty percent of the patients in the poor prognosis group achieved a pathological complete response, and after 25 months, only 19 of them relapsed. None of the patients with a good prognosis received a response, which suggests tumors with a poor prognosis rating from MammaPrint are sensitive to chemotherapy. Other medical headlines: Radix Acupuncture & Chiropractic opens Leading women's health site gets makeover |
||||
